China's API Industry Poised for Transformation Amid Structural Upgrades and New Growth Drivers

The expansion of China's active pharmaceutical ingredient (API) market is currently characterised by dual trends of overall growth and structural optimisation, according to industry analysis.

The bulk API sector is witnessing production efficiency gains, particularly for traditional products like antibiotics and vitamins, through the adoption of continuous manufacturing technologies. Some manufacturers are shifting to biological fermentation methods to replace chemical synthesis, resulting in reduced carbon emissions. However, influenced by global overcapacity and intense price competition, growth in this segment has plateaued, with a notable widening in profit margins among different enterprises. Research indicates that future competitiveness will be determined by capabilities in cost control, economies of scale, and environmental compliance, prompting a phase of further market consolidation.

Conversely, the specialty API sector is experiencing accelerated breakthroughs in high-barrier products, including anticancer, cardiovascular, and central nervous system drugs. These are becoming significant new growth drivers for the industry. Bolstered by a wave of global patent expiries and the advancement of China's generic drug consistency evaluation policy, market demand remains robust. One company, for instance, successfully captured market share by optimising the manufacturing process for a diabetes drug API developed for an international pharmaceutical firm, thereby shortening the research and development cycle. Research forecasts project that specialty APIs will constitute over 30% of the total market by 2030, with an average annual growth rate exceeding 12%.

Meanwhile, the patented API sector, operating on a Contract Development and Manufacturing Organisation (CDMO) model, is poised for significant opportunities. This potential is driven by the global trend of outsourcing innovative drug research and development and the concurrent rise of China's domestic innovative pharmaceutical industry. The CDMO model demands exceptionally high standards in R&D capability, quality management systems, and intellectual property protection, making it a quintessential technology- and capital-intensive field. Research data shows that leading Chinese enterprises have secured a strong position in the international market by undertaking global innovative drug outsourcing orders. Their products, having obtained certifications from regulatory bodies like the US FDA and the European EMA, have established these firms as core suppliers for multiple multinational pharmaceutical corporations.

Industry Chain Transforms from 'Vertical Division' to 'Ecosystem Collaboration'

A significant transformation is underway within the API industry chain, moving from a traditional vertical division of labour towards a model of integrated ecosystem collaboration.

In the upstream segment of basic chemicals, China's large-scale production of bulk raw materials such as benzene and phenol provides stable cost support for the API industry. Nonetheless, the implementation of stricter environmental policies has compelled some high-pollution enterprises to exit the market, leading to temporary shortages of certain intermediates. Simultaneously, a reliance on imports for some high-end critical intermediates persists, representing a potential supply chain risk. In response, Chinese companies are intensifying research and development efforts in green chemistry and continuous flow processes. For example, one enterprise developed a novel catalyst that reduced production costs for a specific API while significantly minimising waste emissions.

In midstream manufacturing, companies are progressively forming an integrated 'API + formulation' model through technological upgrades and supply chain extension. This strategy enhances their value-added capabilities and resilience against risks. Some firms are adopting greener processes, including biofermentation and continuous flow reaction technology, to reduce energy consumption and pollution while improving both production efficiency and product quality. Others are implementing a 'China +1' strategy by establishing production bases in regions such as Southeast Asia and the Middle East, aiming to circumvent trade barriers and position themselves closer to evolving market demands.

In downstream formulation applications, the deepening implementation of volume-based procurement policies has heightened demands from formulation companies for consistent API quality and stringent cost control. This pressure is fostering closer collaboration between API and formulation manufacturers. Industry analysis suggests that over the next five years, leading companies will seek to diversify their business portfolios by building integrated systems encompassing areas like 'nutritional products + APIs + polymer materials' to mitigate cyclical risks. Concurrently, leveraging advancements in internet healthcare and digital therapeutics, they are exploring digital synergies with downstream partners. The establishment of comprehensive drug traceability systems and intelligent supply chains is expected to enhance market responsiveness and service capabilities.

China's API industry stands at a critical juncture, navigating both cyclical fluctuations and structural opportunities. Industry analysts project that over the next five years, the sector will exhibit a development pattern of 'overall growth with structural optimisation'. They anticipate that market share for traditional bulk APIs will gradually consolidate among leading companies, while specialty APIs and biopharmaceutical APIs will emerge as the primary new growth engines. The widespread adoption of green production and intelligent technologies is forecast to be the main driver behind the industry's transition towards high-quality development.